Introduction {#s1}
============

Rheumatoid arthritis (RA), a chronic autoimmune disease, can cause cartilage and bone damage as well as disability. RA is characterized by joint inflammation, but is more like a syndrome that consists of extra-articular manifestations, such as rheumatoid nodules, pulmonary involvement or vasculitis, and systemic comorbidities ([@B25]). RA can present at any age, affects about 1% of the population, and carries a huge emotional and financial burden for both the individual and society ([@B17]). Because inflammation is the main driving factor to cause clinical symptoms, joint damage, disability, and comorbidity in RA patients, anti-inflammation is a key therapeutic strategy ([@B24]). At present, the anti-RA drugs include disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs in western country ([@B25]). However, traditional Chinese medicine (TCM) plays a vital complementary role in treating RA in China ([@B34]). For the past few years, TCM has been increasingly important strategy for treatment of RA in China due to its good therapeutic effect and low toxic side effects.

Chinese Pharmacopoeia shows that *Lamiophlomis rotata* (Benth.) Kudo (LR) can be used to treat RA, and LR patent medicines (Duyiwei capsule or tablet) are legally allowed to trade in China. It was reported that LR showed favorable clinical effect and safety on RA ([@B32]), and a meta-analysis indicated that LR was effective and safe in treating bleeding, pain, and inflammation ([@B30]). In addition, animals experiment indicated that LR could significantly inhibit the formation of primary and secondary arthritis in rats ([@B31]). At present, the active ingredients and mechanisms of LR against RA has not been reported. Therefore, the studies on active ingredients and mechanisms of LR against RA should be strengthened to provide scientific evidence to support its clinical application in treating RA.

Network pharmacology, a systematic analytical method, can analyze the interaction network of multiple factors such as drugs, protein target, diseases, and genes ([@B4]). Network pharmacology can decipher the mechanism of drugs action with a holistic perspective, which emphasizes the paradigm shift from "one target, one drug" to "network target, multicomponent therapeutics" ([@B5]). The characteristic is also shared by TCM, and the holistic theory has long been central to TCM treatments of various diseases ([@B10]). Therefore, network pharmacology is a very advantageous technology to explore TCM-related issues. At present, network pharmacology has been widely used to investigate the active ingredients and mechanisms of TCM against various diseases ([@B28]; [@B2]).

In this work, network pharmacology was used to investigate the active ingredients and mechanisms of LR against RA. First, compounds from LR were identified using literature retrieval, and were screened by absorption, distribution, metabolism, excretion, and toxicity (ADMET) evaluation. Then, genes related to selected compounds or RA were identified using public databases, and the overlapping genes between compounds and RA target genes were identified. Third, the key active ingredients and hub genes of LR against RA were identified by analyzing the interactions between compounds and overlapping genes. Finally, pathway enrichment analysis of overlapping genes was carried out to explore the molecular mechanisms of LR against RA. The workflow is shown in [**Figure 1**](#f1){ref-type="fig"}.

![Workflow of network pharmacology analysis.](fphar-10-01435-g001){#f1}

Materials and Methods {#s2}
=====================

Compounds Database Construction and ADMET Evaluation {#s2_1}
----------------------------------------------------

The information of compounds from LR were collected by retrieving literatures in CNKI (<http://www.cnki.net/>), WANFANG DATA (<http://www.wanfangdata.com.cn/>), Baidu Xueshu (<http://xueshu.baidu.com/>), Web of Science and Google Scholar, and the SMILES and molecular formulas of compounds were identified using SciFinder (<https://scifinder.cas.org/>), PubChem (<https://pubchem.ncbi.nlm.nih.gov/>), or ChemSpider (<http://www.chemspider.com/>) with the aid of compounds names or structure. Then, compounds were screened by applying ADMET criteria of FAFDrugs4 (<http://fafdrugs4.mti.univ-paris-diderot.fr/>) ([@B19]) with the aid of SMILES, and the "PhysChem Filters" of FAFDrugs4 was set as "*Drug-Like Soft.*" Compounds were selected out as potential active ingredients when the result of ADMET evaluation was "Accepted."

Target Genes Linked to Selected Compounds or RA {#s2_2}
-----------------------------------------------

Based on SMILES, target genes of the identified compounds were predicted using STITCH (<http://stitch.embl.de/>) ([@B26]) with the "*Homo sapiens*" setting. To get more credible target genes of each compound, compound with the highest "Tanimoto score," usually 1.000 (match *via* InChIKey), was used to predict the genes of target compound, and the target genes were screened by setting "minimum required interaction score" as "high confidence (0.700)" during performing STITCH prediction ([@B9]).

RA-related target genes were identified by retrieving public databases including Online Mendelian Inheritance in Man (OMIM, <https://omim.org/>), Therapeutic Target Database (TTD, <http://bidd.nus.edu.sg/group/cjttd/>) ([@B12]), Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, <http://lsp.nwu.edu.cn/tcmsp.php>) ([@B21]), and DisGeNET (<http://www.disgenet.org/>). The overlapping genes between compounds and RA target genes were identified and visualized by Venn diagram, plotted using the OmicShare tools, a free online platform for data analysis ([www.omicshare.com/tools](www.omicshare.com/tools)).

Network Construction of Interactions Between Compounds and Overlapping Genes {#s2_3}
----------------------------------------------------------------------------

The interactions between compounds and overlapping genes were obtained based on the results of STITCH prediction, and the network of the interactions was constructed, visualized, and analyzed by Cytoscape ver. 3.7.1 (<https://cytoscape.org/>). Nodes in network indicate compounds and genes, and edges suggest interactions between compounds and genes ([@B9]). The key active ingredients and hub genes of LR against RA were selected out by setting "Degree value" of compounds or genes, identified by analyzing topological structure of network. Degree value of compounds or genes represents the edges numbers of compounds or genes in network. The bigger degree value of compounds or genes are, the more important compounds or genes are for the therapeutic effect of LR on RA.

Pathway Enrichment Analysis of Overlapping Genes {#s2_4}
------------------------------------------------

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of overlapping genes was carried out on Database for Annotation, Visualization, and Integrated Discovery ver. 6.8 (<https://david.ncifcrf.gov/>) with the "*Homo sapiens*" setting. The results of KEGG pathway enrichment were used to decipher the potential molecular mechanisms of LR against RA. Bubble chart of interested KEGG pathways was plotted by the OmicShare tools.

Results {#s3}
=======

Potential Active Ingredients From LR {#s3_1}
------------------------------------

A total of 148 compounds in LR were identified by literatures retrieval, and the names, molecular formulas of these compounds are listed in [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}. The ADMET screen results of 148 compounds showed that the results of 67 compounds were "Accepted," indicating that the 67 compounds exhibited good potential as active ingredients. These compounds are listed in [**Table 1**](#T1){ref-type="table"}.

###### 

A list of the final selected 67 compounds in LR for network analysis based on ADMET screen.

  No.   Compound                                                           No.   Compound
  ----- ------------------------------------------------------------------ ----- --------------------------------
  1     (−)-α-terpineol-8-O-β-D-glucopyranoside                            35    gentisic acid
  2     (+)-α-terpineol-8-O-β-D-glucopyranoside                            36    hexanoic acid
  3     (2Z)-2,6-dimethyl-6-hydroxyocta-2,7-dienyl-O-β-D-glucopyranoside   37    homoprotocatechuic acid
  4     (E)-4-hydroxyhex-2-enoic acid                                      38    hydroxytyrosol
  5     (Z)-3-hexenyl glucopyranoside                                      39    icariside H1
  6     1-hydroxy-2,3,5-trimethoxyxanthone                                 40    isololiolide
  7     2,4,5-trihydroxycinnamic acid                                      41    isorhamnetin
  8     3,4-dihydroxybenzaldehyde                                          42    lamiolactone
  9     3β-hydroxy-5α,6α-epoxy-7-megastigmen-9-one                         43    lamiophlomiol A
  10    4'-(p-carbonylphenyl)-luteolin                                     44    lamiophlomiol B
  11    4-hydroxybenzoic acid                                              45    lamiophlomiol C
  12    5-hydroxyloganin                                                   46    lamiophlomiol D
  13    7,8-dehydropenstemonoside                                          47    lamiophlomiol E
  14    7,8-dehydropenstemoside                                            48    lamiophlomiol F
  15    7-dehydroxyzaluzioside                                             49    lamiophlomis alkali
  16    7-deoxyloganic acid                                                50    loganin
  17    7-deoxyloganin                                                     51    loliolide
  18    7-epiloganin                                                       52    luteolin
  19    8-deoxyshanzhiside                                                 53    n-butyl-β-D-fructofuranoside
  20    8-epi-7-deoxyloganin                                               54    n-butyl-β-D-fructopyranoside
  21    8-epideoxyloganic acid                                             55    notohamosin B
  22    acacetin                                                           56    penstemoside
  23    apigenin                                                           57    phlorigidoside C
  24    apigetrin                                                          58    protocatechuic acid
  25    caffeic acid                                                       59    quercetin
  26    cedrol                                                             60    rhexifoline
  27    chlorogenic acid                                                   61    salicylaldehyde
  28    chlorotuberoside                                                   62    salidroside
  29    cyclohexylglycine                                                  63    salviifoside A
  30    dibutyl phthalate                                                  64    shanzhiside methyl ester
  31    dodecanoic acid                                                    65    syringic acid
  32    esculetin                                                          66    tricin
  33    eugenyl-O-β-D-glucopyranoside                                      67    vanillyl-O-β-D-glucopyranoside
  34    genkwanin                                                                

ADMET, absorption, distribution, metabolism, excretion and toxicity; LR, Lamiophlomis rotate.

Target Genes Linked to the 67 Compounds or RA {#s3_2}
---------------------------------------------

As shown in [**Supplementary Table S2**](#SM1){ref-type="supplementary-material"}, a total of 90 genes related to 25 compounds from abovementioned 67 compounds were identified using STITCH prediction, and no genes linked to another 42 compounds were identified based on STITCH prediction. As listed in [**Supplementary Table S3**](#SM1){ref-type="supplementary-material"}, a total of 1,871 RA-related genes were identified by retrieving OMIM, TTD, TCMSP, and DisGeNET databases. The results of Venn diagram ([**Figure 2**](#f2){ref-type="fig"}) suggested 48 overlapping genes were identified by matching 90 compounds-related genes with 1,871 RA-related genes.

![Overlapping genes between 1,871 rheumatoid arthritis (RA)-related genes **(A)** and 90 compounds-related genes **(B)**.](fphar-10-01435-g002){#f2}

Key Active Ingredients and Hub Genes of LR Against RA {#s3_3}
-----------------------------------------------------

The interactions between 48 overlapping genes and compounds were identified based on the results of STITCH prediction, and 23 compounds were finally identified. The interactions between 48 overlapping genes and 23 compounds are listed in [**Table 2**](#T2){ref-type="table"}, and were visualized by network, which includes with 71 nodes and 68 edges ([**Figure 3**](#f3){ref-type="fig"}). The results suggested that the therapeutic effect of LR on RA was directly related to the 23 compounds and 48 genes. The 23 compounds were categorized as nine flavonoids (luteolin, apigenin, acacetin, isorhamnetin, genkwanin, 1-hydroxy-2,3,5-trimethoxyxanthone, quercetin, tricin, and apigetrin), five phenolic acids (gentisic acid, syringic acid, homoprotocatechuic acid, protocatechuic acid, and 4-hydroxybenzoic acid), four iridoids (loganin, 7-epiloganin, lamiophlomiol D, and lamiolactone), two volatile oil (dibutyl phthalate and salicylaldehyde), one coumarin (esculetin), one phenylethanoid glycoside (salidroside), and one polyphenol (hydroxytyrosol). Based on the degree value of each compound or gene ([**Table 3**](#T3){ref-type="table"}), it was very easy to distinguish the contribution difference of 23 compounds and 48 genes to LR against RA. Luteolin ([**Figure 4**](#f4){ref-type="fig"}), connected to nine genes, was considered as the uppermost active ingredient of LR against RA. AKT1, connected to five compounds, was considered as the hub gene of LR against RA.

###### 

A list of the interactions between 23 compounds in LR and 48 target genes related to RA.

  No.   Compound                             Gene      No.   Compound                  Gene
  ----- ------------------------------------ --------- ----- ------------------------- ---------
  1     1-hydroxy-2,3,5-trimethoxyxanthone   CYP1A2    35    genkwanin                 CYP1A2
  2     1-hydroxy-2,3,5-trimethoxyxanthone   CYP2B6    36    gentisic acid             FGF1
  3     4-hydroxybenzoic acid                CA2       37    gentisic acid             G6PD
  4     7-epiloganin                         CTGF      38    gentisic acid             CA2
  5     acacetin                             IL5       39    homoprotocatechuic acid   TH
  6     acacetin                             SELE      40    homoprotocatechuic acid   ALDH1A3
  7     acacetin                             VEGFA     41    hydroxytyrosol            BCL2
  8     acacetin                             IL13      42    isorhamnetin              NOS2
  9     acacetin                             STAT1     43    isorhamnetin              MAPK9
  10    acacetin                             CYP1A2    44    isorhamnetin              HMOX1
  11    acacetin                             JUN       45    isorhamnetin              MAPK8
  12    apigenin                             CDK1      46    isorhamnetin              AKT1
  13    apigenin                             PTGS2     47    lamiolactone              GAPDH
  14    apigenin                             ESR1      48    lamiophlomiol D           GAPDH
  15    apigenin                             CASP3     49    loganin                   CTGF
  16    apigenin                             PARP1     50    luteolin                  CCNA2
  17    apigenin                             TP53      51    luteolin                  CASP3
  18    apigenin                             AKT1      52    luteolin                  EGFR
  19    apigetrin                            ADIPOQ    53    luteolin                  FOS
  20    dibutyl phthalate                    NR1I3     54    luteolin                  MAPK8
  21    dibutyl phthalate                    ESR1      55    luteolin                  CDK2
  22    dibutyl phthalate                    VEGFA     56    luteolin                  AKT1
  23    dibutyl phthalate                    PLA2G1B   57    luteolin                  JUN
  24    dibutyl phthalate                    SRC       58    luteolin                  MMP9
  25    dibutyl phthalate                    NR1I2     59    protocatechuic acid       MPO
  26    dibutyl phthalate                    AR        60    quercetin                 MCL1
  27    esculetin                            NFE2L2    61    salicylaldehyde           AR
  28    esculetin                            MAPK14    62    salidroside               CASP3
  29    esculetin                            CASP3     63    salidroside               IL10
  30    esculetin                            MAPK8     64    salidroside               HIF1A
  31    esculetin                            MAPK3     65    salidroside               AKT1
  32    esculetin                            TP53      66    syringic acid             DHFR
  33    esculetin                            AKT1      67    syringic acid             MPO
  34    genkwanin                            DUSP1     68    tricin                    CCL2

LR, Lamiophlomis rotate; RA, rheumatoid arthritis.

![Network with 71 nodes and 68 edges linking 23 compounds in *Lamiophlomis rotata* and 48 target genes related to rheumatoid arthritis.](fphar-10-01435-g003){#f3}

###### 

Degree value of 23 compounds and 48 target genes in network.

  No.   Compound                             Value   No.   Gene     Value   No.   Gene      Value
  ----- ------------------------------------ ------- ----- -------- ------- ----- --------- -------
  1     luteolin                             9       1     AKT1     5       25    TH        1
  2     apigenin                             7       2     CASP3    4       26    PTGS2     1
  3     acacetin                             7       3     CYP1A2   3       27    DUSP1     1
  4     esculetin                            7       4     MAPK8    3       28    CCNA2     1
  5     dibutyl phthalate                    7       5     MPO      2       29    IL13      1
  6     isorhamnetin                         5       6     ESR1     2       30    MCL1      1
  7     salidroside                          4       7     VEGFA    2       31    CCL2      1
  8     gentisic acid                        3       8     CTGF     2       32    STAT1     1
  9     syringic acid                        2       9     CA2      2       33    PARP1     1
  10    homoprotocatechuic acid              2       10    TP53     2       34    HMOX1     1
  11    genkwanin                            2       11    GAPDH    2       35    IL10      1
  12    1-hydroxy-2,3,5-trimethoxyxanthone   2       12    JUN      2       36    PLA2G1B   1
  13    hydroxytyrosol                       1       13    AR       2       37    EGFR      1
  14    protocatechuic acid                  1       14    NOS2     1       38    FOS       1
  15    quercetin                            1       15    CDK1     1       39    G6PD      1
  16    tricin                               1       16    BCL2     1       40    MAPK3     1
  17    loganin                              1       17    IL5      1       41    HIF1A     1
  18    7-epiloganin                         1       18    FGF1     1       42    SRC       1
  19    4-hydroxybenzoic acid                1       19    MAPK9    1       43    CDK2      1
  20    lamiophlomiol D                      1       20    SELE     1       44    ALDH1A3   1
  21    lamiolactone                         1       21    DHFR     1       45    CYP2B6    1
  22    salicylaldehyde                      1       22    NFE2L2   1       46    NR1I2     1
  23    apigetrin                            1       23    NR1I3    1       47    MMP9      1
                                                     24    MAPK14   1       48    ADIPOQ    1

![Chemical structure of luteolin.](fphar-10-01435-g004){#f4}

Potential Molecular Pathways of LR Against RA {#s3_4}
---------------------------------------------

The results of KEGG pathway enrichment analysis indicated that 48 overlapping genes were significantly enriched in 74 signaling pathways (*p* \< 0.05). Based on the extensive literature retrieval, the 34 signaling pathways ([**Figure 5**](#f5){ref-type="fig"}) were directly related to occurrence and development of RA, indicating that these signaling pathways might be the mechanisms of LR against RA. The detailed information of top 10 pathways is shown in [**Table 4**](#T4){ref-type="table"}. In addition, the hub gene AKT1 of LR against RA was directly enriched in 27 signaling pathways of the 34 signaling pathways. Coincidently, AKT1 plays a role in almost all of the 27 signaling pathways by PI3K-Akt signaling pathway, suggesting that PI3K-Akt signaling pathway might be the hub signaling pathway of LR against RA.

![Bubble chart of 34 signaling pathways related to occurrence and development of rheumatoid arthritis.](fphar-10-01435-g005){#f5}

###### 

Target genes in top 10 of pathway enrichment related to occurrence and development of RA.

  Pathway ID   Term                                   Target genes
  ------------ -------------------------------------- -----------------------------------------------------------------------------
  hsa04668     TNF signaling pathway                  AKT1, FOS, CASP3, CCL2, PTGS2, MAPK14, JUN, MMP9, MAPK3, MAPK9, MAPK8, SELE
  hsa04917     Prolactin signaling pathway            AKT1, FOS, MAPK14, MAPK3, TH, ESR1, MAPK9, MAPK8, STAT1, SRC
  hsa04066     HIF-1 signaling pathway                AKT1, EGFR, HIF1A, HMOX1, BCL2, MAPK3, VEGFA, NOS2, GAPDH
  hsa04010     MAPK signaling pathway                 AKT1, EGFR, FOS, CASP3, DUSP1, MAPK14, JUN, MAPK3, TP53, MAPK9, MAPK8, FGF1
  hsa04915     Estrogen signaling pathway             AKT1, EGFR, FOS, JUN, MMP9, MAPK3, ESR1, SRC
  hsa04664     Fc epsilon RI signaling pathway        AKT1, IL5, MAPK14, MAPK3, MAPK9, IL13, MAPK8
  hsa04620     Toll-like receptor signaling pathway   AKT1, FOS, MAPK14, JUN, MAPK3, MAPK9, MAPK8, STAT1
  hsa04722     Neurotrophin signaling pathway         AKT1, MAPK14, JUN, BCL2, MAPK3, TP53, MAPK9, MAPK8
  hsa04012     ErbB signaling pathway                 AKT1, EGFR, JUN, MAPK3, MAPK9, MAPK8, SRC
  hsa04380     Osteoclast differentiation             AKT1, FOS, MAPK14, JUN, MAPK3, MAPK9, MAPK8, STAT1

RA, rheumatoid arthritis.

Discussion {#s4}
==========

Compounds-genes network suggested that the therapeutic effect of LR on RA was directly related to 23 compounds, including nine flavonoids, five phenolic acids, four iridoids, two volatile oil, one coumarin, one phenylethanoid glycoside, and one polyphenol. The ratio of flavonoids to 23 compounds was close to 40%, suggesting that flavonoids were more important than other kinds of compounds for the therapeutic effect of LR on RA. Based on the degree value of each compound in compounds-genes network, luteolin was considered as the uppermost active ingredient of LR against RA. It was reported that flavonoids were the key active ingredients group of LR ([@B13]), and flavonoids are used to control the quality of LR patent medicines (Duyiwei capsule or tablet) in Chinese Pharmacopoeia. Studies suggested that luteolin inhibited the proliferation and partially blocked the pathogenic function of synovial fibroblasts in RA ([@B6]; [@B14]). Meanwhile, TCMSP suggests that luteolin is related to occurrence and development of RA ([@B21]). Additionally, it was reported that the quantity of luteolin in LR was about 0.9% ([@B33]), and the clinical dosage of LR patent medicines is 9 g/day based on Chinese Pharmacopoeia, suggesting that the daily intake of luteolin 81 mg in clinic. Study indicated that luteolin showed obvious anti-RA effect on mice with collagen type II-induced RA at a dose of 1 mg/kg/day ([@B7]), which is far lower than the equivalent dose of luteolin in mice, suggesting that the quantity of luteolin in LR is high enough to be of pharmacological relevance.

Compounds-genes network showed that the therapeutic effect of LR on RA was directly related to 48 genes. The results of KEGG pathway enrichment analysis of 48 genes suggested that 34 signaling pathways were directly linked to occurrence and development of RA, indicating that these signaling pathways might be the mechanisms of LR against RA. The relationships of the top 10 pathways with RA were briefly discussed as follows. TNF signaling pathway: The occurrence and development of RA can be suppressed by inhibiting the overexpression of TNF-α, and antibody therapy against TNF-α can effectively reduce the arthritis and synovitis symptoms of RA patients ([@B16]). Prolactin signaling pathway and estrogen signaling pathway: Sex hormones such as estrogen and prolactin have long been thought to be directly related to occurrence and development of RA, and recent evidence indicated that estrogen and prolactin showed both anti- and pro-inflammatory effects in RA ([@B29]). HIF-1 signaling pathway: Clinical research exhibited that HIF-1alpha level was strongest in the sub-lining layer of RA synovium and was linked to synovium inflammation and angiogenesis in RA patients ([@B1]). MAPK signaling pathway: It was reported that andrographolide showed protective effects on RA through inhibiting MAPK pathways, suggesting that MAPK signaling pathway was related to occurrence and development of RA ([@B11]). Fc epsilon RI signaling pathway: Report indicated that IgE, the initiation factor in Fc epsilon RI signaling pathway, may be involved in some extra-articular manifestations of RA ([@B18]). Toll-like receptor signaling pathway: Previous reports indicated that Toll-like receptor and the signaling pathway were intensively linked to RA pathogenesis ([@B27]). Neurotrophin signaling pathway: Report suggested that the level of mesencephalic astrocyte-derived neurotrophic factor was closely related to occurrence and development of RA ([@B15]). ErbB signaling pathway: It was reported that ErbB-2 was involved in occurrence and development of RA ([@B8]). Osteoclast differentiation: Reports exhibited that activated RA synovial fibroblasts played a vital role in rheumatoid bone destruction by expressing osteoclast differentiation factor ([@B22]).

Based on the degree value of each gene in compounds-genes network, AKT1 was considered as the hub gene of LR against RA. AKT1 was directly enriched in 27 signaling pathways of the abovementioned 34 signaling pathways. Coincidently, AKT1 plays a role in almost all of the 27 signaling pathways by PI3K-Akt signaling pathway, suggesting that PI3K-Akt signaling pathway might be the hub signaling pathway of LR against RA. Joint synovium is the main diseased region in RA patients, and its out-of-control proliferation to cartilage and bone causes release of inflammatory cytokines, resulting in occurrence of RA. Therefore, inducing apoptosis of synovial cells is also a feasible strategy for treating RA by preventing development of inflammation ([@B20]). It was reported that PI3K-Akt signaling pathway was abnormally activated in RA synovium, resulting in the overexpression of anti-apoptotic genes such as FLIP, Bcl-2, and Mcl-1 ([@B3]). The overexpression of these anti-apoptotic genes lead to out-of-balance apoptosis of synovial cells, which induced occurrence and development of RA ([@B23]). Reports indicated that luteolin, the uppermost active ingredient of LR against RA, inhibited the proliferation of synovial fibroblasts in RA by blocking PI3K-Akt signaling pathway ([@B6]). Therefore, the key mechanism of LR against RA might be to induce apoptosis of synovial cells by inactivating PI3K-Akt signaling pathway.

Conclusion {#s5}
==========

The active ingredients and mechanisms of LR against RA were firstly investigated using network pharmacology. The findings of this work suggested that the active ingredients and target genes of LR against RA consisted of 23 compounds and 48 genes, and luteolin and AKT1 were the uppermost active ingredient and hub gene of LR against RA, respectively. The mechanisms of LR against RA were related to 34 signaling pathways, and the key mechanism of LR against RA might be to induce apoptosis of synovial cells by inactivating PI3K-Akt signaling pathway. This work provides scientific evidence to support the clinical effect of LR on RA, and a research basis for further expounding the active ingredients and mechanisms of LR against RA.
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